Novo Nordisk beats earnings expectations as Wegovy, Ozempic demand soars

Novo Nordisk, Europe's largest company by market capitalization, on Wednesday reported better-than-expected 2023 earnings, as sales of its wildly popular anti-obesity and diabetes drugs continued to soar.The maker of weight loss drug Wegovy and diabetes drug Ozempic reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates (CER) to 232.3 billion kroner ($33.71 billion).Full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion kroner ...